Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bariatric Surgery vs Semaglutide vs Tirzepatide in Obesity
NCT06803888Phase 4Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide and tirzepatide in obesity (3 arms). Primary endpoint: Mean percentage total body weight loss at 52 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06803888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803888.